β淀粉样肽聚集抑制剂体外筛选模型的建立及木栓酮抑制活性研究  

Development of an assay for screening β amyloid aggregation inhibitors in vitro and study on inhibitive activity of friedelin

作　　者：赵彬[1] 杨红军[2] 赵晶[1] 

机构地区：[1]成都军区昆明总医院医学实验科,云南昆明650032 [2]昆明医学院第一附属医院,云南昆明650031

出　　处：《中国药学杂志》2005年第19期1474-1477,共4页Chinese Pharmaceutical Journal

基　　金：云南省自然科学基金(2002C0023Q)

摘　　要：目的从天然药物中筛选β淀粉样肽聚集抑制剂。方法建立β淀粉样肽聚集抑制剂筛选模型的酶联免疫吸附测定(ELISA)检测方法,同时使用刚果红结合试验和硫磺素T分析试验对部分中草药提取物进行活性筛选,并对活性部位进行分离跟踪。结果灯盏细辛乙醇提取物显示β淀粉样肽聚集抑制活性,经跟踪分离测定发现其所合成分木栓酮为抑制作用活性成分。结论成功地建立了一种基于ELISA原理的β淀粉样肽聚集抑制剂筛选模型;用该模型筛选到灯盏细辛提取物及其所含化学成分木栓酮具有抑制β淀粉样肽体外聚集的活性。OBJECTIVE To screen the inhibitors ofβ amyloid aggregation from natural products.METHODS A screening assay was established based on ELISA theory to screen the inhibitors ofβ amyloid aggregation. The inhibition was determined by congo red binding assay and thioflavin T binding assay. Some herbs were screened. The active compounds were isolated and tracing detected. RESULTS The ethanol extract of Erigeron breviscapine （vant） was found to be active, the active component was isolated and elucidated as friedelin. CONCLUSION A screen assay is successfully established based on ELISA theory for screening the inhibitors of the β amyloid aggregation in vitro. Friedelin prevents the aggregation of syntheticβ amyloid in vitro.

关 键 词：Β淀粉样肽 抑制 聚集 木栓酮 灯盏细辛 

分 类 号：R979.9[医药卫生—药品]